

EMA/366015/2018

European Medicines Agency decision

P/0172/2018

of 15 June 2018

on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir (Sovaldi), (EMA-001276-PIP01-12-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0172/2018

of 15 June 2018

on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir (Sovaldi), (EMA-001276-PIP01-12-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0294/2012 issued on 18 December 2012 and the decision P/0178/2014 issued on 7 July 2014,

Having regard to the application submitted by Gilead Sciences International Ltd. on 5 February 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 April 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for sofosbuvir (Sovaldi), film-coated tablet, age-appropriate oral solid dosage form, age-appropriate oral dosage form, other, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Gilead Sciences International Ltd., Flowers Building, Granta Park, Abingdon, CB21 6GT - Cambridge, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/88448/2018

London, 27 April 2018

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-001276-PIP01-12-M02

Scope of the application

Active substance(s):

Sofosbuvir

Invented name:

Sovaldi

Condition(s):

Treatment of chronic hepatitis C

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral solid dosage form

Age-appropriate oral dosage form, other

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Gilead Sciences International Ltd.

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Gilead Sciences International Ltd. submitted to the European Medicines Agency on 5 February 2018 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0294/2012 issued on 18 December 2012 and the decision P/0178/2014 issued on 7 July 2014.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 27 February 2018.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic hepatitis C

The waiver applies to:

- the paediatric population from birth to less than 3 years of age;
- film-coated tablet, age-appropriate oral solid dosage form, and age-appropriate oral dosage form, other, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specific paediatric subset.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of chronic hepatitis C

2.1.1. Indication(s) targeted by the PIP

Treatment of children 3 years of age and older and adolescents who have chronic hepatitis C genotype 2 or 3 infection and who are positive for HCV-RNA in a combination regimen with ribavirin

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral solid dosage form

Age-appropriate oral dosage form, other

2.1.4. Studies

Area	Number of studies	Description
Quality-related studies	2	Study 1: Development of an age-appropriate oral solid dosage form Study 2: Development of an age-appropriate oral dosage form, other
Non-clinical studies	0	Not applicable

Clinical studies	1	Study 3: Open-label, single-arm trial to evaluate pharmacokinetics, safety and efficacy of sofosbuvir plus ribavirin in children from 3 to less than 18 years of age with genotypes (GT) 2 or 3 chronic hepatitis C virus (HCV) infection
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2018
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):**1. Treatment of Chronic Hepatitis C infection****Authorised indication(s):**

- Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and in adolescents aged 12 to <18 years (see sections 4.2, 4.4 and 5.1).

For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use